Literature DB >> 35799243

Comment to the Description of a Novel Cohesinopathy in Chronic Intestinal Pseudo Obstruction.

Elena Bonora1, Francesca Bianco1,2, Roberto De Giorgio3.   

Abstract

Entities:  

Year:  2022        PMID: 35799243      PMCID: PMC9274473          DOI: 10.5056/jnm22017

Source DB:  PubMed          Journal:  J Neurogastroenterol Motil        ISSN: 2093-0879            Impact factor:   4.725


× No keyword cloud information.
TO THE EDITOR: We read with great interest the article “A novel cohesinopathy causing chronic intestinal pseudo obstruction in 2 siblings and literature review” by Venkatesh et al[1] reporting on a gene mutation in 2 patients with a clinical phenotype of chronic intestinal pseudo-obstruction (CIPO). The topic of the genetic analysis in rare forms of severe gut dysmotility is extremely cogent in the neurogastroenterology area especially because the management of CIPO is still largely ineffective and mainly centered on general measures (hydro-electrolyte balance and adequate caloric support often via parenteral nutrition). Thus, investigating genetic and molecular mechanisms may unveil novel therapeutic approaches for this orphan disorder. In any affected patient, either adult or pediatric, CIPO is characterized by a marked derangement of gut propulsion, mimicking a mechanical sub-occlusion, in the absence of any anatomical cause of obstruction. The severity of the clinical presentation is typically associated with disabling digestive symptoms, which contribute to poor quality of life and increased mortality. In the last years, several genetic causes have been identified in different subsets of CIPO patients. Heterozygous mutations in the ACTG2 gene were found in patients with CIPO characterized by degeneration of enteric smooth muscle, as well as in the “megacystis, microcolon, and intestinal hypoperistalsis” syndrome.[2-5] X-linked CIPO has been ascribed to filamin A gene mutations.[6,7] TYMP, POLG, and LIG3 genes have been demonstrated in recessive forms of mitochondrial CIPO.[8-10] Finally, homozygous mutations in SGOL1 and RAD21 genes, encoding for members of the cohesin complex, have been identified in another subset of CIPO in association with additional clinical manifestations, ie, chronic atrial and intestinal dysrhythmia (CAID),[11] or cardiac defect and long Barrett esophagus in Mungan’s syndrome,[12,13] respectively. Both SGOL1 and RAD21 mutations are known to be causative of these 2 forms of “cohesinopathy” underlying CIPO. In this context, Venkatesh et al[1] identified a homozygous variant in SGOL1 in 2 siblings using next-generation sequencing analysis. The mutation was correctly interpreted to be causative, although the authors did not inform whether a target gene panel analysis, whole exome or whole genome sequencing was performed. These methodological approaches are of critical importance to exclude the presence of other putative variants of interest. Moreover, the identified variant (p.Lys23Glu) is exactly the same of that reported by Chetaille et al[11] who showed a causative homozygous variant in several Canadian pedigrees with patients affected by CIPO and atrial dysrhythmia (hence CAID, as previously mentioned). We address this in order to avoid possible misinterpretation by the reader. It would be always important to report the genomic coordinates and the dbSNP ID of a variant, as in the current case (rs199815268). This finding facilitates comparison between studies and can help identifying clinical convergence and/or differences among CIPO patients. Furthermore, the segregation of the selected variants should be pursued when possible in order to confirm that the pattern(s) of inheritance is/are correct. Since there was no report of consanguinity in the family reported by Venkatesh et al,[1] it would be very important to prove that both parents were heterozygous carriers, maybe again due to a founder effect in the corresponding geographical area, as observed in the original paper by Chetaille et al[11] in the described Canadian families. In conclusion, we commend Venkatesh et al[1] for their effort aimed at identifying CIPO-causative variants, which is a pivotal approach to better understand the molecular defects underlying this difficult and highly challenging condition. However, data regarding mutations of any detected variants should be carefully detailed to provide a clear-cut understanding for all readers.
  13 in total

1.  Biallelic variants in LIG3 cause a novel mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Elena Bonora; Sanjiban Chakrabarty; Georgios Kellaris; Makiko Tsutsumi; Francesca Bianco; Christian Bergamini; Farid Ullah; Federica Isidori; Irene Liparulo; Chiara Diquigiovanni; Luca Masin; Nicola Rizzardi; Mariapia Giuditta Cratere; Elisa Boschetti; Valentina Papa; Alessandra Maresca; Giovanna Cenacchi; Rita Casadio; Pierluigi Martelli; Ivana Matera; Isabella Ceccherini; Romana Fato; Giuseppe Raiola; Serena Arrigo; Sara Signa; Angela Rita Sementa; Mariasavina Severino; Pasquale Striano; Chiara Fiorillo; Tsuyoshi Goto; Shumpei Uchino; Yoshinobu Oyazato; Hisayoshi Nakamura; Sushil K Mishra; Yu-Sheng Yeh; Takema Kato; Kandai Nozu; Jantima Tanboon; Ichiro Morioka; Ichizo Nishino; Tatsushi Toda; Yu-Ichi Goto; Akira Ohtake; Kenjiro Kosaki; Yoshiki Yamaguchi; Ikuya Nonaka; Kazumoto Iijima; Masakazu Mimaki; Hiroki Kurahashi; Anja Raams; Alyson MacInnes; Mariel Alders; Marc Engelen; Gabor Linthorst; Tom de Koning; Wilfred den Dunnen; Gerard Dijkstra; Karin van Spaendonck; Dik C van Gent; Eleonora M Aronica; Paolo Picco; Valerio Carelli; Marco Seri; Nicholas Katsanis; Floor A M Duijkers; Mariko Taniguchi-Ikeda; Roberto De Giorgio
Journal:  Brain       Date:  2021-04-15       Impact factor: 13.501

2.  Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction.

Authors:  Elena Bonora; Francesca Bianco; Lina Cordeddu; Michael Bamshad; Ludmila Francescatto; Dustin Dowless; Vincenzo Stanghellini; Rosanna F Cogliandro; Greger Lindberg; Zeynel Mungan; Kivanc Cefle; Tayfun Ozcelik; Sukru Palanduz; Sukru Ozturk; Asuman Gedikbasi; Alessandra Gori; Tommaso Pippucci; Claudio Graziano; Umberto Volta; Giacomo Caio; Giovanni Barbara; Mauro D'Amato; Marco Seri; Nicholas Katsanis; Giovanni Romeo; Roberto De Giorgio
Journal:  Gastroenterology       Date:  2015-01-06       Impact factor: 22.682

3.  Segregation of a missense variant in enteric smooth muscle actin γ-2 with autosomal dominant familial visceral myopathy.

Authors:  Heli J Lehtonen; Taina Sipponen; Sari Tojkander; Riitta Karikoski; Heikki Järvinen; Nigel G Laing; Pekka Lappalainen; Lauri A Aaltonen; Sari Tuupanen
Journal:  Gastroenterology       Date:  2012-09-06       Impact factor: 22.682

4.  Familial visceral myopathy with pseudo-obstruction, megaduodenum, Barrett's esophagus, and cardiac abnormalities.

Authors:  Zeynel Mungan; Filiz Akyüz; Zehra Bugra; Oya Yönall; Sükrü Oztürk; Arif Acar; Ugur Cevikbas
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

Review 5.  New perspectives in the diagnosis and management of enteric neuropathies.

Authors:  Charles H Knowles; Greger Lindberg; Emanuele Panza; Roberto De Giorgio
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-02-12       Impact factor: 46.802

6.  Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder.

Authors:  I Nishino; A Spinazzola; M Hirano
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

7.  Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy.

Authors:  Gert Van Goethem; Marianne Schwartz; Ann Löfgren; Bart Dermaut; Christine Van Broeckhoven; John Vissing
Journal:  Eur J Hum Genet       Date:  2003-07       Impact factor: 4.246

8.  Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction.

Authors:  Ivana Matera; Marta Rusmini; Yiran Guo; Margherita Lerone; Jiankang Li; Jianguo Zhang; Marco Di Duca; Paolo Nozza; Manuela Mosconi; Alessio Pini Prato; Giuseppe Martucciello; Arrigo Barabino; Francesco Morandi; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Ravazzolo; Marcella Devoto; Hakon Hakonarson; Isabella Ceccherini
Journal:  Eur J Hum Genet       Date:  2016-01-27       Impact factor: 4.246

9.  Heterozygous de novo and inherited mutations in the smooth muscle actin (ACTG2) gene underlie megacystis-microcolon-intestinal hypoperistalsis syndrome.

Authors:  Michael F Wangler; Claudia Gonzaga-Jauregui; Tomasz Gambin; Samantha Penney; Timothy Moss; Atul Chopra; Frank J Probst; Fan Xia; Yaping Yang; Steven Werlin; Ieva Eglite; Liene Kornejeva; Carlos A Bacino; Dustin Baldridge; Jeff Neul; Efrat Lev Lehman; Austin Larson; Joke Beuten; Donna M Muzny; Shalini Jhangiani; Richard A Gibbs; James R Lupski; Arthur Beaudet
Journal:  PLoS Genet       Date:  2014-03-27       Impact factor: 5.917

10.  Xq28 duplication presenting with intestinal and bladder dysfunction and a distinctive facial appearance.

Authors:  Jill Clayton-Smith; Sarah Walters; Emma Hobson; Emma Burkitt-Wright; Rupert Smith; Annick Toutain; Jeanne Amiel; Stanislas Lyonnet; Sahar Mansour; David Fitzpatrick; Roberto Ciccone; Ivana Ricca; Orsetta Zuffardi; Dian Donnai
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.